A recent comparative effectiveness analysis compared type 2 diabetes drugs based on mortality and cardiovascular events. The study assessed SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors. Researchers concluded that SGLT-2 inhibitors and GLP-1 agonists were associated with lower all-cause and cardiovascular mortality while DPP-4 inhibitors were not, potentially recommending the former two over the latter as add-on therapies to metformin.